Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 464,029 shares of the medical research company's stock, valued at approximately $19,369,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.31% of Bruker at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pinnacle Bancorp Inc. bought a new position in shares of Bruker in the 1st quarter valued at approximately $29,000. Allworth Financial LP raised its stake in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. Fifth Third Bancorp increased its position in Bruker by 54.2% in the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after buying an additional 390 shares during the period. Finally, Quadrant Capital Group LLC increased its position in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after buying an additional 196 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.
Bruker Trading Up 3.7%
NASDAQ:BRKR traded up $1.49 on Friday, reaching $41.94. The company's stock had a trading volume of 3,519,763 shares, compared to its average volume of 2,322,538. Bruker Corporation has a 1-year low of $34.10 and a 1-year high of $72.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. The firm has a market cap of $6.36 billion, a PE ratio of 80.65, a PEG ratio of 2.69 and a beta of 1.18. The business's 50-day moving average price is $39.47 and its two-hundred day moving average price is $44.41.
Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same period in the previous year, the firm earned $0.53 earnings per share. The company's revenue was up 11.0% on a year-over-year basis. Equities research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.48%. Bruker's dividend payout ratio is currently 38.46%.
Analysts Set New Price Targets
Several analysts have recently weighed in on BRKR shares. UBS Group decreased their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and reduced their price objective for the stock from $50.00 to $40.00 in a research note on Thursday, May 22nd. Wells Fargo & Company dropped their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Stifel Nicolaus dropped their target price on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. Finally, Barclays dropped their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $52.89.
Get Our Latest Report on Bruker
Insider Buying and Selling at Bruker
In other news, CEO Frank H. Laukien acquired 2,608 shares of Bruker stock in a transaction dated Friday, June 6th. The stock was bought at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.30% of the stock is owned by corporate insiders.
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Read More

Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.